about
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusImpact of nighttime and weekend liver transplants on graft and patient outcomes.Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.A 52-year-old man with heartburn: should he undergo screening for Barrett's esophagus?Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literaturePredicting Liver Transplant Capacity Using Discrete Event SimulationDecreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witnessPersistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy.Practice patterns in screening for varices: an American survey.Focal fat masquerading as malignancy in the liver graft of a post-transplant patient.Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitisSingle-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography for treatment of cholangitis in a patient with a Kasai portoenterostomy.Intestinal microbiota in liver disease.Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death.Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.A histologic scoring system for prognosis of patients with alcoholic hepatitisDisparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USALocal access to subspecialty care influences the chance of receiving a liver transplant.Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation.Colder weather and fewer sunlight hours increase alcohol consumption and alcoholic cirrhosis worldwideMixed Cryoglobulin-induced Esophageal Necrosis in a Patient With Hepatitis CComplications Associated with Anesthesia Services in Endoscopic Procedures Among Patients with CirrhosisMarijuana Consumption in Liver Transplant RecipientsLetter to the Editor: Proton Pump Inhibitors in Cirrhosis: A Marker of Morbid Conditions or a Cause of Mortality?
P50
Q26830190-971ACEC6-2CA9-4D98-A4FD-F6E9AFB1FE45Q34249228-5DB1EDD1-2C29-4BC5-9DC3-F06CA5DD1CDCQ34491823-FE71F9D0-0294-445A-B95D-BBAC07AC8FEDQ34777601-486C81AF-00F3-4877-A15E-4331B658FA04Q35109416-4502990E-36D0-4E94-B9A9-A6BB0B5F3588Q35598452-6703CF99-FD5F-483D-92D8-187440326B68Q35602372-AE64E0A8-EEC1-4572-96E6-2BF38C073A6CQ35796397-A1590F7E-28CB-4D90-8AD6-A47079BC9534Q35796445-4B01B116-1971-4467-9B20-73611DF7959AQ35796467-5D5B19F0-F7C8-482C-9DE9-5ACF37EC39C9Q35840922-AE07D30A-66FE-4353-A980-058A76526D84Q35842935-353BFF27-86DA-4F1C-9B39-8CB30610042AQ35975114-A9A134E9-A326-44E9-A517-32627A657A63Q35980635-FEBA32BA-36D6-4E60-A6B9-B36A580580DAQ36503848-6D65DA1A-87AA-4A1A-A3EC-56F7FC754E19Q36933104-BB8798E4-F906-44BF-B9BF-62B43AFC8069Q37212963-5CCF98C2-386F-43AF-8D67-814643C53BD7Q37710980-62D02941-EEBC-44C3-BB4D-04DD5748E64FQ37728503-E031AC54-8FD5-4D67-A360-A72B6841386CQ38065139-DA2348AA-26E9-4D54-9BC3-1302B19C4CFCQ38196327-C3D18461-5A6F-4F76-B0EE-DBF30B95053CQ39537347-30B69125-5D7B-4EC2-BB21-8EB3506202FDQ41172019-F2FB1BF4-A73C-4F39-9971-FFF9352B086AQ42024851-5AB9B5B6-6587-4AEF-A0CE-3BE3D1F6CA49Q54842741-E1F5FA11-51A0-49D0-9216-F2FF261E8413Q57457485-888E9868-42C7-4F4B-9B38-A92F86AC8858Q89099916-44151956-E42E-4DA6-A485-B9DD3854F9ECQ90174248-D19CA4CA-C5BD-49F1-9772-3995DD74D081Q91262696-DEF7DF3A-D0A3-41BB-BDF5-9C00D2896CB1Q92874972-B2CC2708-A49A-4998-BFBB-23B0015A412F
P50
description
researcher ORCID ID = 0000-0002-4200-3256
@en
wetenschapper
@nl
name
Alfred S Barritt
@ast
Alfred S Barritt
@en
Alfred S Barritt
@es
Alfred S Barritt
@nl
type
label
Alfred S Barritt
@ast
Alfred S Barritt
@en
Alfred S Barritt
@es
Alfred S Barritt
@nl
prefLabel
Alfred S Barritt
@ast
Alfred S Barritt
@en
Alfred S Barritt
@es
Alfred S Barritt
@nl
P1153
35578215500
57190740757
P21
P31
P496
0000-0002-4200-3256